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Glucosamine supplementation during late
gestation alters placental development and
increases litter size
Jeffrey L. Vallet1*, Jeremy R. Miles1, Bradley A. Freking1 and Shane Meyer2
Abstract
Background: During late gestation the placental epithelial interface becomes highly folded, which involves
changes in stromal hyaluronan. Hyaluronan is composed of glucoronate and N-acetyl-glucosamine. We
hypothesized that supplementing gestating dams with glucosamine during this time would support placental
folded-epithelial-bilayer development and increase litter size. In Exp. 1, gilts were unilaterally hysterectomized-
ovariectomized (UHO). UHO gilts were mated and then supplemented daily with 10 g glucosamine (n = 16) or
glucose (control, n = 17) from d 85 of gestation until slaughter (d 105). At slaughter, the number of live fetuses was
recorded and each live fetus and its placenta was weighed. Uterine wall samples adjacent to the largest and
smallest fetuses within each litter were processed for histology. In Exp. 2, pregnant sows in a commercial sow farm
were supplemented with either 10 g glucosamine or glucose daily from d 85 of gestation to farrowing. Total
piglets born and born alive were recorded for each litter. In Exp. 3, the same commercial farm and same protocol
were used except that the dose of glucosamine and glucose was doubled to 20 g/d.
Results: In Exp. 1, the number of live fetuses tended to be greater in glucosamine-treated UHO gilts (P = 0.098).
Placental morphometry indicated that the width of the folded bilayer was greater (P = 0.05) in glucosamine-treated
gilts. In Exp. 2, litter size did not differ between glucosamine- and glucose-treated sows. However in Exp. 3, the
increased dose of glucosamine resulted in a significant treatment by parity interaction (P ≤ 0.01), in which total
piglets born and born alive were greater in glucosamine treated sows of later parity (5 and 6).
Conclusions: These results indicated that glucosamine supplementation increased the width of the folds of the
placental bilayer and increased litter size in later parity, intact pregnant commercial sows.
Keywords: Fructose, Glucosamine, Hyaluronan, Swine, Uterine capacity
Background
Litter size contributes to the profitability of swine pro-
duction, and is influenced by ovulation rate, fertilization
rate, embryonic mortality and uterine capacity [1].
Fertilization rate and embryonic mortality are typically
fixed rates that are independent of oocyte or embryo
number [1, 2]. Thus, a greater ovulation rate results in
increased embryos at d 30 of gestation [3]. However,
greater ovulation rate does not result in greater litter
size at farrowing [4], but does reduce birth weight [3]. In
addition, conceptus losses under crowded uterine
conditions occur throughout gestation [3, 5]. Both phe-
nomena are the result of reduced placental size caused
by intrauterine crowding.
Recent studies suggest that the pig placenta compen-
sates for reduced intrauterine space [6]. A component of
this adaptation is likely to be increased depth of the
microscopic folds of the placental epithelial bilayer [7].
However, Vallet and Freking [7] also reported that pla-
centa of small fetuses lacked stromal tissue above the
folded bilayer, especially during late gestation, potentially
limiting the compensatory ability of the placenta. Hya-
luronan is a major component of placental stroma [8, 9]
and is composed of repeating units of N-acetyl glucosa-
mine and glucuronate, which are both derivatives of glu-
cose [10]. Interestingly, Glucose transporter (GLUT) 2,
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which is present at the fetal maternal interface [11], has
greater transport capacity for glucosamine compared to
glucose [12]. We hypothesized that supplementation of
glucosamine in sow diets might preferentially promote
placental stromal development, allowing increased pla-
cental epithelial bilayer fold development. This would in-
crease uterine capacity of glucosamine-treated sows. The
objective of these experiments was to test whether glu-
cosamine supplementation alters placental fold develop-
ment, uterine capacity and litter size.
Methods
Experiment 1
Gilts were unilaterally hysterectomized-ovariectomized
(UHO) at 160 d of age. Gilts were anesthetized with so-
dium pentothal and anesthesia was maintained using
fluothane. The UHO surgery involves removing one
ovary and one uterine horn, and reduces the total intra-
uterine space by one-half, while the ovulation rate re-
mains unaffected. The litter size of pigs after UHO is no
longer affected by ovulation rate, and is considered to be
a measure of one-half their uterine capacity [5]. Gilts
were fed 2 kg/d of a diet that met NRC requirements for
pigs, consisting of 70% ground corn, 25% soybean meal
with the remainder made up of vitamin and mineral
supplements, free lysine and soybean oil. Gilts were
allowed to recover and were subsequently naturally
mated to mature boars after at least one estrous cycle of
normal length (17 to 23 d). Thirty-three pregnant UHO
gilts were used in this experiment. Beginning at d 85 of
gestation, gilts were fed in individual pens and received
either 10 g glucosamine (Hard Eight Nutrition LLC,
Henderson NV) or 10 g glucose (Pastry Chef Central
Inc., Boca Raton FL) as a top dress on their daily feed.
The dose of glucosamine was chosen to be similar to
that routinely used for supplementation in humans, after
accounting for differences in weight (1.5 to 3 g per day
are recommended in adult humans). Supplementation
on d 85 of gestation was chosen because secondary fold
development begins at this time [13]. Secondary fold de-
velopment requires significant stromal remodeling and
hyaluronan turnover. Because hyaluronan is 50% glu-
cosamine, we hypothesized that glucosamine supple-
mentation would facilitate fold development by
supporting hyaluronan turnover. At 105 d of gestation,
gilts were humanely slaughtered and the remaining uter-
ine horn and ovary were collected. Corpora lutea were
counted, and the umbilical cord of each live fetus was
exteriorized through a small antimesometrial hole in the
uterine wall to minimize disruption of the placental vas-
culature. Then, blood samples were taken from each
fetus. A fetus was considered alive if it had a visible
pulse in the exposed umbilical cord. Blood samples were
taken from the umbilical artery of each live fetus. The
remaining uterine horn was then opened completely and
each live fetus was counted and weighed. The largest
and smallest fetuses by weight were identified, their cor-
responding placentas were identified, and a uterine wall
sample was collected that included these placentas. The
smallest live fetus in each litter was chosen as this would
be the most compromised fetus within the UHO litter. It
was compared to the largest fetus in the litter as this
would be the most uncompromised fetus in the litter.
Thus, sampling the largest and smallest fetuses repre-
sented the full range of weight variation within each lit-
ter. Uterine samples were taken immediately adjacent
but external to the amnion. Tissues were placed into
cassettes and immersed in buffered formalin. Finally, a
further sample of fetal placental tissue was collected and
frozen in liquid nitrogen.
After formalin fixation, uterine wall samples were
transferred to 70% ethanol in water, dehydrated through
a series of increasing alcohol concentrations followed by
xylene, and then embedded in paraffin. Tissues were
then sectioned (10 μm), placed on slides, rehydrated and
stained with hematoxylin and eosin, dehydrated and cov-
erslipped. At least two sections were evaluated for each
placental sample. Width of the folded bilayer, width of
the stroma above the folds, and the interface length ad-
justed to constant placental length were measured using
Bioquant (Bioquant image analysis corporation, Nash-
ville, TN) as previously described [7], includes figure de-
scribing individual measures. Briefly, to obtain these
measures, the area of a folded region within the placen-
tal interface was obtained by creating a closed polygon
that extended from the base of the first fold to its top,
across the top of several (3 to 5) adjacent folds, from the
top to the bottom of the last fold, and across the bottom
of the adjacent folds. Then, the length of the polygon
along the long axis of the folded bilayer was measured
by drawing a line through the center of the folded region
within the polygon. The average width of the polygon
(width of the folded bilayer) was calculated as the area
of the polygon divided by its length. The width of the
stroma was measured from the tip of each fold within
the polygon to the adjacent edge of the stroma (border
of the allantois). These measures were averaged for each
slide to provide a single stromal width measure for each
slide. Finally, the adjusted placental interface length was
obtained by measuring (i.e., tracing) the length of the
folded bilayer within the polygon, and dividing that
length by the length of the polygon through the center.
Each of the three measures was then averaged for the
two slides for each placenta to provide a single measure
of the width of folds, width of stroma and adjusted pla-
cental interface length for each placenta.
Fetal blood samples were allowed to clot, centrifuged,
and serum was collected. Serum samples from each fetus
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were measured for glucose and fructose. Glucose was
measured using the YSI 2700 Biochemistry Analyzer
(YSI Life Sciences, Yellow Springs, OH) using instruc-
tions included in the manual. Fructose was measured
using the procedure described by Zavy et al. [14].
Placental tissue samples were homogenized as de-
scribed by Vallet et al. [9] and homogenates were mea-
sured for hyaluronan using a kit (Corgenix Inc.,
Broomfield CO). Homogenized placental samples were
diluted 1:500 in PBS before assay.
Experiment 2
This trial took place at a commercial sow farm in Neb-
raska (Plymouth Ag Group, Diller, NE) in May–July,
2015. The farm farrowed approximately 255 sows over a
two-week period in weekly batches. Sow parity in both
weeks ranged from 2 to 8. Sows were managed (includ-
ing diet) and bred by artificial insemination according to
the normal protocols existing at the farm, and were then
supplemented with either glucosamine (n = 128; 10 g/d)
or glucose (n = 127; control, 10 g/d) as a top dress on
their daily feed (~2 kg corn-soybean diet depending on
body condition) beginning on d 85 of gestation. Care
was taken to evenly distribute glucosamine or glucose
treatment among parities. Top dress was delivered using
plastic scoops previously calibrated to deliver the appro-
priate amounts of glucosamine or glucose. During gesta-
tion, sows were housed in individual gestation stalls
according to the standard procedure for the farm, all-
owing for them to be dosed independently on a daily
basis. At d 115 of gestation, sows received an injection
of estrumate (cloprostenol; Merck Animal Health,
Madison, NJ) to induce farrowing, which is also standard
procedure for the management of farrowing on the farm.
Number born, number born alive, number stillborn,
number of mummified fetuses, and the number of pig-
lets weaned were recorded for each litter. All live piglets
were ear tagged at birth, and birth and weaning weights
for each live piglet were also recorded for each litter.
Piglets were crossfostered according to procedures used
on the commercial farm, but it was not possible to rec-
ord piglet movement except at weaning. Piglets were
weaned at an average age of 19.6 d (range 11 to 28 d).
Experiment 3
This trial took place at the same commercial sow farm
as described for Exp. 2, in May–July, 2016. The protocol
used was the same as that described for Exp. 2, except
that the dose of glucose and glucosamine was increased
to 20 g/d, to account for the larger sows compared to
the gilts in Exp. 1. In addition, only parity 3 to 7 sows
were treated, no parity 2 sows were available within the
management system at the time of the trial. In this ex-
periment, 89 sows received glucosamine and 87 sows
received glucose. As in Exp. 2, piglets were ear tagged
and weighed and then crossfostered after birth but it
was not possible to record crossfostering until piglets
were weighed at weaning.
Statistical analysis
Fetal number (uterine capacity) data from Exp. 1 was an-
alyzed using PROC MIXED (SAS Inst. Inc., Cary, NC)
with a model that included treatment. Fetal blood glu-
cose and fructose were analyzed with a model that in-
cluded treatment, fetal weight, placental weight, and
treatment by fetal weight and treatment by placental
weight interactions. Gilt within treatment was included
as a random effect. Interaction terms that were not sig-
nificant were sequentially dropped from the model to ar-
rive at a final model. Placental morphometry and
hyaluronan data were analyzed using a model that in-
cluded effects of treatment, fetal size and the treatment
by size interaction. Gilt within treatment was included
as a random effect. Relationships between placental hya-
luronan and fetal serum glucose and fructose for the
corresponding largest and smallest fetuses were analyzed
using a model that included treatment, fetal size, the
treatment by fetal size interaction, fetal weight, fetal
weight by treatment, fetal weight by fetal size, fetal
weight by treatment by fetal size, placental weight, pla-
cental weight by treatment, placental weight by fetal size,
and placental weight by treatment by fetal size. Nonsig-
nificant effects were sequentially removed from the
model, starting with complex interactions, until only sig-
nificant effects remained.
Litter size data from Exp. 2 and 3 were analyzed using
PROC MIXED with a model that included the effects of
farrowing week, treatment, parity and the treatment by
parity interaction. Orthogonal contrasts were used when
necessary to further evaluate differences among treat-
ment means. Birth and weaning weights were considered
repeated measures of the birth dam and were therefore
analyzed with a similar model to litter size data, includ-
ing effects of farrowing week, treatment, parity and the
treatment by parity interaction. Sow within week by
treatment by parity interaction was included as a ran-
dom effect. Finally, stillbirth rate and preweaning mor-
tality were also considered a trait of the birth dam and
analyzed using PROC GLIMMIX, treating alive or dead
at birth and weaning as binary variables. Because it was
not possible to record crossfostering, crossfostering was
considered to be random and was not considered in the
analysis of preweaning mortality. Thus, this analysis
treats weaning weights and preweaning mortality as
traits of the birth dam, not traits of the lactating dam.
The model included effects of farrowing week, treat-
ment, parity and treatment by parity, and the effect of
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sow within week by treatment by parity was included as
a random effect.
Results
Experiment 1
Number of CL for glucosamine- and glucose-treated UHO
gilts did not differ (16.2 ± 0.9 and 15.1 ± 0.9, respectively).
There was a trend (P = 0.098) toward greater number of
live fetuses in UHO gilts treated with glucosamine com-
pared to glucose (8.4 ± 0.6 and 6.9 ± 0.6, respectively).
There were no treatment interaction effects on the re-
lationships between fetal weight and fetal serum glucose
and placental weight and fetal serum glucose, nor was
there an overall effect of treatment on fetal serum glu-
cose when interaction effects were removed from the
model. However, both fetal weight and placental weight
were associated (P < 0.05) with fetal serum glucose, and
these relationships are illustrated in Fig. 1. The surface
plot in Fig. 1 indicates that fetal serum glucose de-
creased with increasing fetal weight and increased with
increasing placental weight (fetal glucose = − 0.0072
(fetal weight) + 0.002401 (placental weight)). The two ef-
fects balanced (no net effect on glucose concentrations)
when placental weights were 30% of fetal weights (white
line indicated in Fig. 1).
Fetal serum fructose relationships with fetal and pla-
cental weights were affected by treatment, and the ef-
fects are illustrated in Fig. 2. The final model included
significant treatment by fetal weight (P < 0.01) and treat-
ment by placental weight (P < 0.05) interaction terms. In
glucosamine-treated gilts, fetal serum fructose was
positively related to both fetal weight and placental
weight (fetal serum fructose = 5.6916 + 0.00098 (fetal
weight) + 0.00185 (placental weight)). In glucose-treated
gilts, fetal serum fructose was positively related to fetal
weight and negatively related to placental weight (fetal
serum fructose = 6.1504 + 0.00438 (fetal weight) –
0.01363 (placental weight)). Similar to relationships be-
tween fetal weight, placental weight and fetal serum glu-
cose, the effects of fetal weight and placental weight on
fetal serum fructose in glucose treated gilts balanced
when placental weight was 32% of fetal weight (white
line in Fig. 2a). Few live fetuses were present in the data-
set where the placenta was greater than 30% of fetal
weight at d 105 of gestation.
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Fig. 1 Effect of fetal and placental weight on fetal serum glucose.
Both fetal weight and placental weight affected fetal serum glucose
concentrations, with no effect of glucosamine supplementation
(glucose = 2.06–0.00072(fetal weight) + 0.002401(pwt); P < 0.05 for
both effects). The white line indicates where the effects of fetal and
placenta weights on glucose balance, yielding no change in glucose
concentrations. This occurs at a ratio of placental weight to fetal
weight of 0.30. Means with number of observations are included at
positions within the surface plot to reflect how well the surface plot
corresponds with the actual observations
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Fig. 2 Effect of fetal and placental weight on fetal serum
fructose-glucosamine treated (a), glucose treated (b). Response
surfaces differed between treatments (fructose = 5.6916 + 0.00098(fetal
weight) + 0.00185(placental weight) for glucosamine supplemented
gilts; fructose = 6.1504 + 0.00438(fetal weight) – 0.01363(placental
weight); slope for fetal weight P = 0.09; slope for placental
weight P < 0.05). Within glucose-treated gilts, the white line indicates
the fructose concentration where the effects of placental and fetal
weight balance, which is at a ratio of 0.32. Means with number of
observations are included at positions within the surface plots to reflect
how well the surface plots corresponds with the actual observations
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Fetal and placental weight, fetal blood glucose and
fructose, and placental hyaluronan for the largest and
smallest fetuses in each litter are summarized in Table 1.
Hyaluronan data from the largest and smallest placentas
from one gilt were unusually high (> 3 standard devia-
tions above the mean), and were therefore deleted as
outliers. There was no effect of treatment or treatment
by fetal size interaction on these traits. Fetal and placen-
tal weights were significantly reduced (P < 0.01) in the
smallest compared to the largest fetuses in the litter.
Despite results from all fetuses within the litter indicat-
ing that glucose decreased with fetal weight, there was
no significant effect of fetal size on fetal serum glucose
in this reduced dataset. Similar to results from all fetuses
in the litter, there was a significant decrease (P < 0.05) in
fructose in the smallest fetus compared to the largest
fetus in the litter. Placental hyaluronan was unaffected
by fetal size as a category, or by fetal weight or placental
weight as continuous variables. Further exploration of
relationships between hyaluronan and fetal serum glu-
cose and fructose using regression analysis indicated that
the relationship between hyaluronan and serum fructose
concentrations was unaffected by treatment or fetal size
and that there was no overall relationship. The relation-
ship between hyaluronan and fetal serum glucose did
not differ between large and small fetuses, but did differ
between treatments (treatment intercepts, P < 0.05;
treatment slopes, P = 0.06; Fig. 3). Placental hyaluronan
was positively related to glucose in glucosamine-treated
gilts, and negatively related to glucose in glucose-treated
gilts.
The results of placental morphometry are summarized
in Table 2. Placental fold width was significantly greater
(P = 0.05) in glucosamine-treated gilts compared to
glucose-treated gilts. There was no effect of size of the
fetus on placental fold width, and there was no treat-
ment by size of fetus interaction. Stromal depth above
the folded bilayer did not differ with treatment or size of
fetus, but there tended to be a treatment by fetal size
interaction (P = 0.07). This appeared to be due to greater
stromal depth in large fetuses from glucosamine-treated
UHO gilts compared to the other three treatment by
fetal size combinations (P < 0.01). The total width of the
placenta was greater (P < 0.05) in glucosamine-treated
gilts compared to glucose-treated gilts, and there was no
effect of fetal size on total placental width nor was there
a treatment by fetal size interaction. Finally, the length
of the folded bilayer adjusted to a constant length of pla-
centa was unaffected by treatment, fetal size or the treat-
ment by fetal size interaction. Nevertheless, the adjusted
length of the folded bilayer was significantly correlated
(r = 0.75; P < 0.01) with the width of the folded bilayer.
Experiment 2
There was a treatment by parity interaction for number
of stillborn piglets and stillbirth rate. No treatment by
parity interaction was observed for any of the other
traits measured in this experiment. The treatment by
parity least squares means for number of stillborn piglets
and stillbirth rate are presented in Table 3. For both
number of stillborns and stillbirth rate, the interaction
appeared to be due to greater stillbirth in glucosamine
supplemented sows in later parities (parities 7 and 8).
Treatment least squares means for the other litter size
and weight traits are presented in Table 4. There were
no statistically significant effects of treatment on the
number of total born, born alive, or mummies, or on
birth weights, weaning weights, or preweaning mortality.
Significant parity effects (Table 5) were observed for
the number of total born (P < 0.05) and live born piglets
(P < 0.05), and for birth (P < 0.01) and weaning weights
(P < 0.05). Number of mummies and preweaning mor-
tality were not affected by parity. Total born and born
alive increased gradually with increasing parity until par-
ity 6, after which both litter size measures decreased.
Birth weights were similar among parities until parity 6,
after which they also decreased (P < 0.05). In contrast,
average weaning weights increased progressively with in-
creasing parity.
Table 1 Treatment effects on fetuses from Experiment 1
Glucosaminea Glucose
Variable Large Small Large Small
Fetal weight, gb 1017 ± 52 529 ± 52 1076 ± 49 639 ± 49
Placental weight, g 231 ± 13 108 ± 13 219 ± 13 129 ± 13
Serum glucose, mmol/L 1.8 ± 0.2 1.7 ± 0.2 1.9 ± 0.2 1.7 ± 0.2
Serum fructose, mmol/Lc 6.7 ± 0.6 5.6 ± 0.6 7.7 ± 0.5 6.7 ± 0.5
Placental hyaluronan, mg/g tissued 1.06 ± 0.11 0.87 ± 0.11 1.08 ± 0.10 1.18 ± 0.10
aNumber of observations is 16 for glucosamine and 17 for glucose. Least squares means for fetal weight, placental weight, serum glucose and fructose and
placental hyaluronan for the smallest and largest fetus in glucosamine and glucose-treated gilts from Exp. 1 are presented
bEffect of fetal size (P < 0.01)
cEffect of fetal size (P < 0.05)
dPlacental hyaluronan results from one sow with very high hyaluronan (> 3 standard deviations above mean) were deleted from the analysis
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Experiment 3
There was an overall effect of treatment (P < 0.05; Total
piglets born 17.9 ± 0.5 for glucosamine, 16.5 ± 0.5 for
glucose; Number born alive 15.9 ± 0.4 for glucosamine,
14.6 ± 0.4 for glucose) and a treatment by parity inter-
action for total piglets born and piglets born alive
(P < 0.01; Table 6). Orthogonal contrasts indicated that
glucosamine treatment resulted in greater total piglets
born and born alive in later parities (5 and 6) compared
to early parities and parity 7. There were no effects of
treatment on the number of stillbirths or mummies.
Analysis of birth and weaning weights indicated that
glucosamine had no effect on weights compared to glu-
cose treatment. Finally, there was no difference in pre-
weaning mortality between the two treatment groups.
Discussion
Results indicated that glucosamine supplementation
tended to improve the number of live fetuses in UHO
gilts (a measure of uterine capacity), altered the micro-
scopic architecture of the developing pig placenta, and
changed relationships between fetal size, fetal serum glu-
cose and fructose, and placental hyaluronan. In Exp. 2,
10 g/d glucosamine supplementation of intact sows in a
commercial herd did not result in a beneficial effect at
the dose used in gilts. One possible contributing factor
to the lack of treatment effect on the number of piglets
born alive in Exp. 2 was an increased number of still-
born piglets in late parity sows treated with glucosamine.
Comparisons of total born, born alive and birth weights
among parities confirmed that reductions in each oc-
curred in parity 7 and 8 sows, so it is possible that some
interaction between the reproductive competence of late
parity sows and glucosamine supplementation may ex-
plain the increase in stillbirth incidence. Because the
dose used in Exp. 2 may not have been sufficient in the
larger sows to observe an effect on litter size, the trial
was repeated in Exp. 3 using 20 g/d. Results of Exp. 3 in-
dicate a substantial (+1.3 piglets born alive overall) gain
in litter size compared to glucose treatment and the ef-
fect was greater in later parity sows.
Glucose and fructose are part of the pathway that re-
sults in glucosamine synthesis [15]. In Exp. 1, serum glu-
cose and fructose concentrations were measured to
determine whether they were altered by glucosamine
supplementation. Results indicated significant relation-
ships for both glucose and fructose with fetal and pla-
cental weights. Glucose concentrations were negatively
related to fetal weight and positively related to placental
weight. These relationships are consistent with the con-
cept that within the conceptus, glucose originates from
the placenta and is used by the fetus [16, 17]. These rela-
tionships were unaffected by treatment. In contrast, fetal
and placental weight relationships with fructose concen-
trations were affected by treatment. Glucose treated gilts
may be considered the “normal” fetal and placental
weight relationships with fructose because a daily dose
of 10 or 20 g glucose added to a diet of 2 kg/d of a corn-
soy diet would not be expected to add much available
glucose to the gestating gilt (the corn-soybean based
daily diet contains at least 1 kg starch, which would be
converted to glucose during digestion). Curiously, in
0
500
1000
1500
2000
2500
3000
0.00 1.00 2.00 3.00 4.00 5.00
P
la
ce
n
ta
l h
ya
lu
ro
n
an
, u
g
/g
 t
is
su
e
Glucose, mmol/L
glucosamine
glucose
glucosamine
glucose
Fig. 3 Effect of glucose on hyaluronan by treatment. Heterogeneity
of regression indicated that the two lines differed (glucosamine
supplemented: hyaluronan = 760.44 + 115.77(glucose); glucose
supplemented: hyaluronan = 1427–162.64; P < 0.05 for intercept;
P = 0.06 for slope)
Table 2 Treatment effects on placental morphometry from Experiment 1
Glucosaminea Glucose
Variable Large Small Large Small
Fold Width, μmb 778 ± 37 818 ± 37 716 ± 36 731 ± 36
Stromal Width, μmc 236 ± 28 142 ± 28 140 ± 27 146 ± 27
Total Width, μmb 1014 ± 47 961 ± 47 856 ± 46 876 ± 46
Interface length/unit placental lengthc 7470 ± 403 7546 ± 403 6969 ± 389 6727 ± 389
aNumber of observations is 16 for glucosamine and 17 for glucose. Least squares means for bilayer fold width, stromal width above the folded bilayer, total
placental width and placental bilayer interface length per unit placental length from Exp. 1 are presented
bEffect of treatment (P ≤ 0.05)
cEffect of treatment by fetal size (P = 0.07)
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glucose-treated gilts at d 105 of gestation, fetal plasma
fructose was positively related to fetal weights and nega-
tively related to placental weights. Previous reports indi-
cate that both the placenta and the fetus are sources of
fructose during gestation [18, 19]. Results from glucose
supplemented gilts suggest that at d 105 of gestation, the
placenta may be a net consumer of fructose and the
fetus may be a net producer of fructose. Glucosamine
supplementation resulted in reducing the positive rela-
tionship with fetal weight, and converting the negative
relationship with placental weight to a positive one, es-
sentially stabilizing fructose concentrations as fetal and
placental weights vary (Fig. 2). These changes could be
consistent with the role of fructose in the synthesis of
glucosamine [15]. Thus, Fig. 2 is consistent with the
concept that providing exogenous glucosamine might re-
duce fructose use by the placenta and stabilize fructose
concentrations.
Hyaluronan is a major component of the placental
stroma [7, 8]. Glucosamine is a major component of
hyaluronan, the other component being glucuronic acid
[9]. The folded bilayer interface undergoes extensive re-
modeling during late gestation (d 85 onward), character-
ized by increased stromal development between individual
folds and development of secondary folds [7, 13]. These
processes likely require both synthesis of new hyaluronan
and turnover of existing hyaluronan. This is likely to re-
quire the synthesis of both glucuronic acid and glucosa-
mine, which both originate from glucose [20], although
fructose is an intermediate in glucosamine synthesis [15].
Paradoxically, glucosamine supplementation altered the
relationship between serum glucose and placental hyalur-
onan, and no relationship between fructose and hyaluro-
nan was demonstrated, despite fructose being an
intermediate in glucosamine synthesis. However, no differ-
ence in placental hyaluronan occurred between treat-
ments. It is possible that glucosamine altered the
relationship between hyaluronan and glucose by improv-
ing turnover without affecting fructose, which may have
made the placenta more efficient at glucose transport,
resulting in a positive relationship. This possible mechan-
ism would be supported by changes in the microscopic
architecture of the placental folds.
Results indicated increased total thickness of the pla-
centa, increased width of the folded bilayer, and in-
creased stromal depth above the folded bilayer in
placenta of large fetuses. These changes are all consist-
ent with the concept that glucosamine encourages stro-
mal development, and that this in turn provides the
substrate needed to encourage folded bilayer develop-
ment. Given our previous hypothesis [7], one would ex-
pect improvement in placental transport of nutrients.
However, if nutrient transport was improved, one might
expect an increase in fetal weight, especially for small fe-
tuses. No change in the weight of the smallest fetus was
observed. On the other hand, it is possible that there is a
threshold weight of the smallest living fetus for fetal sur-
vival. If this is true, the weight of the smallest living fetus
might be unchanged, but more fetuses would survive be-
cause more fetuses would be above the survival thresh-
old as a result of improved transport. Thus, the trend in
greater litter size in glucosamine-treated gilts observed
in this experiment supports the hypothesis that the im-
provements in fold development resulted in improved
nutrient transport that then increased litter size.
The UHO surgical procedure removes one ovary and
one uterine horn, and the remaining ovary undergoes
compensatory hypertrophy such that ovulation rate is
unaffected. This results in the same number of available
embryos in half the uterine space, and litter size in UHO
gilts is considered to be a direct measure of one-half
uterine capacity [5]. Results of experiment 1 indicated a
Table 4 Treatment effects on litter traits from Experiment 2
Treatmenta
Variable Glucosamine Glucose
Total born 15.6 ± 0.4 (128) 15.2 ± 0.4 (127)
Born alive 14.0 ± 0.3 13.8 ± 0.3
Mummies 0.56 ± 0.08 0.57 ± 0.08
Birth weights 1.37 ± 0.02 (1970) 1.35 ± 0.02 (1915)
Weaning weights 5.48 ± 0.06 5.43 ± 0.06
Preweaning mortality 0.17 ± 0.01 0.16 ± 0.01
aDifferences between glucosamine and glucose supplementation were not
statistically significant. Number of observations are in parentheses. Litter size
trait, birth and weaning weight least squares means for glucosamine and
glucose supplemented sows from Exp. 2 are presented
Table 3 Treatment by parity effect on number stillborn and
stillbirth rate from Experiment 2
Treatment
Paritya Glucosamine Glucose
Number stillborn Stillbirth rate Number stillborn Stillbirth rate
2 1.0 ± 0.3 (20)b 0.06 ± 0.02 0.8 ± 0.3 (20) 0.06 ± 0.02
3 1.4 ± 0.3 (30) 0.08 ± 0.02 1.0 ± 0.3 (30) 0.07 ± 0.01
4 0.9 ± 0.4 (15) 0.06 ± 0.02 1.3 ± 0.4 (16) 0.07 ± 0.02
5 1.8 ± 0.4 (14) 0.09 ± 0.02 1.8 ± 0.5 (11) 0.11 ± 0.03
6 1.8 ± 0.4 (14) 0.10 ± 0.03 2.2 ± 0.4 (15) 0.11 ± 0.03
7 2.1 ± 0.3 (23) 0.14 ± 0.03 1.5 ± 0.3 (23) 0.10 ± 0.02
8 2.6 ± 0.4 (12) 0.22 ± 0.04 1.2 ± 0.4 (12) 0.09 ± 0.03
aFor both traits, the interaction contrast comparing the interaction between
treatments and parities 2 through 6 combined versus parities 7 and 8
combined was statistically significant (P < 0.05), indicating that more stillborn
piglets occurred in the glucosamine-treated parity 7 and 8 sows compared to
earlier parity sows. Least squares means for the treatment by parity interaction
for number of stillborn piglets and stillbirth rate from Exp. 2 are presented
bNumbers of observations are in parentheses
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numerical increase in litter size of 1.4 live fetuses on 105
d of gestation, so it was conceivable that uterine capacity
was increased by nearly 3 live fetuses. The UHO meas-
ure was uncomplicated by the incidence of stillbirth, be-
cause the measure was made at slaughter on d 105 of
gestation. Previous selection for uterine capacity using
the UHO model resulted in an increase in uterine cap-
acity of approximately one fetus per uterine horn, and a
significant increase in litter size in intact selected gilts,
although the effect on litter size was less due to the in-
fluence of ovulation rate on litter size in intact gilts [21].
Nevertheless, given the results of Exp. 1, it seemed likely
that glucosamine would increase litter size in intact pigs,
thus warranting a larger test in intact sows.
Results of Exp. 2 indicated no significant effect of
10 g/d of glucosamine supplementation on litter size in
sows ranging in parity from 2 to 8 in contrast to the re-
sults of Exp. 1 in which a trend toward improved litter
size was obtained. In Exp. 2, we used the same dose of
glucosamine for sows as for the gilts in Exp. 1. However,
because they were not as old, the gilts in Exp. 1 weighed
less than the sows used in Exp. 2. To explore whether a
greater dose would be effective, we performed a second
commercial trial using 20 g/d glucosamine. Results of
Exp. 3 indicated that a dose of 20 g/d in sows was effect-
ive in increasing both the total number of piglets born
and the number born alive with greater increases occur-
ring in later parity (5 and 6) sows. Analysis of birth and
weaning weights indicated no change in piglet weights
despite the increase in litter size of greater than 1 piglet
per litter; therefore, the increase in litter size occurred
without a depression in birth weights. Finally, there was
no difference in preweaning mortality, indicating that
the increase in litter size should have resulted in an in-
crease in the number of weaned piglets.
An obvious complicating factor in Exp. 2 and 3 is the
ovulation rate of the sows used, which we were not able
to measure because of the commercial setting. Previous
Table 6 Treatment by parity effects on litter traits from experiment 3
Treatment Total borna Born alivea Stillborns Mummies Birth weight Weaning weight Preweaning mortality
Glucosamine
Parity 3 17.9 ± 0.7 15.9 ± 0.7 1.3 ± 0.3 0.8 ± 0.2 1.40 ± 0.04 5.0 ± 0.1 0.11 ± 0.02
Parity 4 16.8 ± 0.9 14.9 ± 0.8 1.3 ± 0.3 0.5 ± 0.2 1.41 ± 0.05 4.9 ± 0.1 0.15 ± 0.02
Parity 5 20.0 ± 1.2 17.2 ± 1.0 1.7 ± 0.5 1.1 ± 0.3 1.26 ± 0.06 5.1 ± 0.2 0.16 ± 0.03
Parity 6 18.7 ± 1.2 17.2 ± 1.1 0.5 ± 0.5 1.0 ± 0.3 1.32 ± 0.07 5.1 ± 0.2 0.17 ± 0.03
Parity 7 16.2 ± 1.0 14.3 ± 0.9 1.5 ± 0.4 0.3 ± 0.2 1.37 ± 0.06 5.2 ± 0.2 0.11 ± 0.02
Glucose
Parity 3 17.6 ± 0.8 16.0 ± 0.7 1.0 ± 0.3 0.6 ± 0.2 1.36 ± 0.04 5.1 ± 0.1 0.11 ± 0.03
Parity 4 17.9 ± 0.9 15.8 ± 0.8 1.5 ± 0.4 0.6 ± 0.2 1.41 ± 0.05 4.8 ± 0.2 0.18 ± 0.03
Parity 5 15.8 ± 1.1 14.7 ± 1.0 0.9 ± 0.4 0.2 ± 0.3 1.42 ± 0.06 4.8 ± 0.2 0.12 ± 0.03
Parity 6 15.1 ± 1.1 12.1 ± 1.0 2.4 ± 0.4 0.6 ± 0.3 1.30 ± 0.06 5.0 ± 0.2 0.24 ± 0.04
Parity 7 15.8 ± 1.1 14.3 ± 0.9 1.1 ± 0.4 0.5 ± 0.3 1.41 ± 0.06 4.8 ± 0.2 0.08 ± 0.02
aA treatment by parity interaction was present. Orthogonal contrasts indicated that total born and born alive were greater in later parities (5 and 6) in glucosamine
treated sows compared to glucose treated sows, but were not different in early parities or in parity 7. Litter size trait, birth and weaning weight least squares means for
glucosamine- and glucose-supplemented sows for each parity from Exp. 3 are presented
Table 5 Parity effects on litter traits from Experiment 2
Parity
Variable 2 3 4 5 6 7 8
Total borna 14.7 ± 0.6(40)b 15.3 ± 0.5(60) 15.5 ± 0.7(31) 16.4 ± 0.8(25) 17.3 ± 0.7(29) 14.4 ± 0.6(46) 14.5 ± 0.8(24)
Born alivea 13.8 ± 0.6 14.1 ± 0.5 14.4 ± 0.6 14.6 ± 0.7 15.3 ± 0.7 12.6 ± 0.5 12.6 ± 0.7
Mummies 0.29 ± 0.14 0.59 ± 0.12 0.64 ± 0.16 0.53 ± 0.18 0.72 ± 0.17 0.69 ± 0.13 0.48 ± 0.18
Birth weightsc 1.45 ± 0.04 1.45 ± 0.03 1.40 ± 0.04 1.39 ± 0.04 1.33 ± 0.04 1.34 ± 0.03 1.33 ± 0.05
Weaning weightsd 5.29 ± 0.09 5.30 ± 0.08 5.34 ± 0.12 5.38 ± 0.12 5.57 ± 0.11 5.67 ± 0.09 5.64 ± 0.13
Preweaning mortality 0.14 ± 0.02 0.15 ± 0.02 0.17 ± 0.02 0.18 ± 0.02 0.16 ± 0.02 0.22 ± 0.02 0.19 ± 0.03
aContrasts indicated a progressive increase to parity 6, followed by a precipitous decrease (P < 0.05). Litter size trait, birth and weaning weight least squares
means for second through eighth parity sows from Exp. 2 are presented
bNumber of observations are in parentheses
cContrasts indicated no differences among parities 2 through 6, and a decrease in parities 7 and 8 (P < 0.01)
d Contrasts indicated a progressive increase from parity 2 to 8 (P < 0.05)
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observations of ovulation rates in commercial sows have
indicated very high ovulation rates, particularly in later
parity sows [22]. High ovulation rates in parity 5 and 6
sows may explain the interaction effect observed. If simi-
lar ovulation rates to those previously reported occurred
in the parity 5 and 6 sows used in our commercial trials,
they are likely to have been sufficient to provide a good
test of uterine capacity in intact females. Ovulation rates
in earlier parity animals may not have been sufficient,
resulting in the interaction observed. The commercial
farm in this experiment obtains maternal line gilts from
DNA genetics (Columbus, NE; formerly Danbred USA),
but we could find no published estimates of ovulation
rates in these maternal line gilts. However, there are
published litter size estimates for Danish maternal line
gilts, demonstrating excellent genetic progress in litter
size selection [23], and it is likely that high ovulation
rates contributed to the reported increase in litter size
due to selection. Thus, ovulation rates were likely to be
high enough in the parity 5 and 6 sows to put greater
emphasis on uterine capacity as a determining factor for
litter size. Exception to this may have been the late par-
ity sows in Exp. 2 and 3 (parity 7 and 8). In Exp. 2 these
sows clearly had reduced numbers of total born and
born alive piglets, and one contributing factor to this de-
crease could have been reduced ovulation rates. We
could not find any published reports of ovulation rates
specifically in sows in later parities for commercial
herds, primarily because previous reports combined ovu-
lation rate estimates of parities 4 or greater [22]. Thus,
whether ovulation rate decreased in parity 7 and 8 sows
under some conditions, resulting in lower litter size, re-
mains unknown.
The increase in the number of stillborn piglets and
stillbirth rates in parity 7 and 8 sows supplemented with
glucosamine in Exp. 2 was an unexpected result. Results
of Exp. 1 indicated that glucosamine supplementation
increased the depth of the folded bilayer in the pig pla-
centa regardless of the size of the fetus, and because of
this the total width of the placenta was increased. Van
Rens and Van der Lende [24] implicated a thicker pla-
centa in prolongation of individual piglet birth intervals,
and suggested that placental thickness may contribute to
stillbirth rate due to the well-known relationship be-
tween piglet birth intervals and stillbirth [25]. Van Rens
and Van der Lende [24] suggested that thicker placentas
may present a greater barrier to delivery of the piglet
during farrowing, increasing birth intervals. However,
the effective width of the placenta is likely to be the
width of the stroma above the folded bilayer, which we
have reported to be reduced in small fetuses compared
to large fetuses [7]. Results of Exp. 1 confirm that the
stroma above the folds is greater in placenta of large
fetuses in gilts supplemented with glucosamine. The
incidence of larger fetuses, and therefore thicker pla-
centa, might be expected to increase with decreasing lit-
ter size. It is possible that the reduced litter size in parity
7 and 8 sows observed in Exp. 2 resulted in thicker pla-
centa in these sows upon glucosamine supplementation,
which could have prolonged birth intervals (which we
did not measure), and increased stillbirth. Whatever the
mechanism for the increase in stillbirth rate, results
from Exp. 2 suggest that glucosamine supplementation
may be detrimental in parity 7 and 8 sows due to in-
creased stillbirth rate.
Conclusions
Maternal supplementation with glucosamine altered fetal
serum glucose and fructose dynamics and increased the
depth of the placental folded bilayer in placenta of UHO
gilts. Results are consistent with the concept that glucosa-
mine supplementation may have stabilized fetal fructose
concentrations as fetal and placental weights vary among
conceptuses. The placental epithelial bilayer fold-depth
changes occurred with a trend toward increased uterine
capacity of about 1.4 fetuses per uterine horn measured in
UHO gilts. In commercial trials, glucosamine supplemen-
tation in intact sows resulted in a slight numerical but
nonsignificant increase in the number of piglets born and
born alive at a dose of 10 g/d glucosamine and a signifi-
cant increase in litter size of greater than 1 piglet per litter
at a dose of 20 g/d. The increased litter size occurred in
later parity 5 and 6 sows. Thus, it is likely that 10 g/d glu-
cosamine was not sufficient in commercial sows due to
their larger size compared to the gilts in Exp. 1. The in-
crease in litter size from a dose of 20 g/d occurred without
reductions in birth or weaning weights and with no reduc-
tion in preweaning mortality. Our results further indicated
an increase in the number of stillborn piglets and stillbirth
rate in glucosamine-treated late parity sows (parity 7 and
8) in Exp. 2, which was unexpected. This may have been
due to the effect of glucosamine supplementation on pla-
cental thickness, which could have occurred due to the re-
duced litter sizes in these late parity sows. These results
suggest that glucosamine supplementation at a dose of
20 g/d could be useful in increasing litter size in commer-
cial parity 5 and 6 sows, resulting in increased number of
piglets weaned. Because the mechanism of the increase is
likely to be based on improved placental function and
uterine capacity, an increase would only be expected if
ovulation rates are sufficient.
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